Biotech: Page
-
Getty Images
Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s
Zealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S. regulators rejected an AbbVie medicine and another well-funded AI drug discovery startup emerged.
By BioPharma Dive staff • June 26, 2024 -
Permission granted by Geron
After 33 years, Geron’s first approval marks a turn in Nobel-winning science
The decades-long story of how a novel type of blood cancer drug went from a scientific idea to an approved product.
By Alexandra Pecci • June 26, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Getty Images
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine
The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.
By Gwendolyn Wu • June 25, 2024 -
Getty Images
Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data
The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.
By BioPharma Dive staff • June 24, 2024 -
Getty Images
Alnylam says heart drug succeeds in closely watched study
Positive results from a Phase 3 trial of vutrisiran in transthyretin amyloidosis cardiomyopathy set up a market competition with Pfizer and BridgeBio.
By Ben Fidler • Updated June 24, 2024 -
Getty Images
Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
By BioPharma Dive staff • June 21, 2024 -
Getty Images
Obesity drug from Zealand shows potential in early trial
Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.
By Jonathan Gardner • June 20, 2024 -
Getty Images
FDA lifts hold on PTC Huntington’s disease trial
The agency has lifted a partial trial suspension based on one-year data showing PTC’s pill suppressed a key protein associated with the disorder.
By Jonathan Gardner • June 20, 2024 -
Getty Images
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
By BioPharma Dive staff • June 18, 2024 -
Permission granted by Kevin Trimmer/Ascidian Therapeutics
Roche partners with RNA editing biotech Ascidian
While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.
By Gwendolyn Wu • June 18, 2024 -
Permission granted by Marea Therapeutics
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.
With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.
By Gwendolyn Wu • June 18, 2024 -
Getty Images
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments
The new company, Spur Therapeutics, is getting another $50 million from Syncona to support its broadened pipeline, which targets Parkinson’s disease as well as heart conditions.
By Jacob Bell • June 17, 2024 -
Getty Images
Immune resetNew data showcase promise, growing pains of CAR-T in autoimmune disease
One expert described trial results presented at EULAR in June as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
By Ben Fidler • June 17, 2024 -
Courtesy of AbbVie
AbbVie joins in latest gastrointestinal drug chase
Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.
By Jonathan Gardner • June 14, 2024 -
Michael M. Santiago via Getty Images
Radiopharma drugmaker Telix pulls US IPO plans
The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange.
By Ned Pagliarulo • June 14, 2024 -
Getty Images
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.
By BioPharma Dive staff • June 14, 2024 -
Joe Raedle/Getty Images via Getty Images
Moderna says next-gen COVID shot effective in study
Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.
By Kristin Jensen • June 13, 2024 -
Permission granted by Versant Ventures
Versant debuts biotech working on ‘anger management for the immune system’
Investor enthusiasm for precision immunology medicines is providing a tailwind for Santa Ana Therapeutics, a new startup backed by Versant, GV and a16z, among others.
By Gwendolyn Wu • June 13, 2024 -
Jeenah Moon via Getty Images
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.
By Delilah Alvarado • June 12, 2024 -
Getty Images
Regenxbio CEO to step down after 15 years
Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.
By Ned Pagliarulo • June 12, 2024 -
Permission granted by Ultragenyx
Ultragenyx, Mereo drug reduces fractures in bone disorder study
New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.
By Kristin Jensen • June 12, 2024 -
Getty Images
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.
By BioPharma Dive staff • June 12, 2024 -
Getty Images
Foresite, a biotech venture firm, reloads with $900M fund
Amid some optimism for biotech startups, the firm sees opportunities to fund companies “at all stages of the productive development life cycle,” said managing director Vik Bajaj.
By Gwendolyn Wu • June 12, 2024 -
Getty Images
Ipsen drug for rare liver disease approved by FDA
The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.
By Ned Pagliarulo • June 11, 2024 -
Michael M. Santiago via Getty Images
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
The offering will help fund Phase 3 tests of a drug the biotech claims could be more selective and potent than Bristol’s TYK2 inhibitor.
By Ben Fidler • June 10, 2024
Previous
